SCHEMBL23833385

SCHEMBL23833385

COc1ncc(NC(=O)c2cnc(-c3ccccc3)[nH]2)cc1S(=O)(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 7/20 0.44
PIK3CD O00329 1/20 0.43
PIK3R1 P27986 1/20 0.43
PIK3CA P42336 1/20 0.43
PIK3CB P42338 1/20 0.43
PIK3CG P48736 1/20 0.43
ALPL P05186 1/20 0.43
AVPR2 P30518 1/20 0.42
GPR27 Q9NS67 1/20 0.42
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
MAPT P10636 4/20 0.41
HTT P42858 2/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 2/20 0.41
MITF O75030 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TNIK Q9UKE5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30151008 1.00 IDH1 (0.44) IDH1PIK3CDPIK3R1PIK3CAPIK3CB
SCHEMBL23840396 0.90 PIK3CD (0.43) IDH1PIK3CDPIK3R1PIK3CAPIK3CB
SCHEMBL25755146 0.89 ALPL (0.54) IDH1ALPLAVPR2GPR27MEN1
SCHEMBL23846436 0.81 LMNA (0.60) ALPLMEN1KMT2AMAPTHTT
SCHEMBL23833363 0.81 TUBB4A (0.50) IDH1PIK3CDPIK3R1PIK3CAPIK3CB
SCHEMBL30151018 0.81 TUBB4A (0.50) IDH1PIK3CDPIK3R1PIK3CAPIK3CB
SCHEMBL25755151 0.80 KMT2A (0.54) IDH1ALPLMEN1KMT2AMAPT
SCHEMBL25755168 0.80 MAPT (0.51) IDH1ALPLMEN1KMT2AMAPT
SCHEMBL20841762 0.80 MAPT (0.60) ALPLGPR27MEN1KMT2AMAPT
SCHEMBL23846497 0.80 LMNA (0.51) PIK3CDPIK3CAPIK3CGALPLMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121030-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF Amathus Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D IDH1 457/4885PIK3CD 680/4885PIK3R1 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.